Tag: biosimilars

New Findings in Sarcoma

Sarcoma is a rare type of cancer, making up about 1 percent of all adult cancers and about 15 percent of pediatric cancers, according to the Liddy Shriver Sarcoma Initiative. Despite the high rate for childhood and adolescent cancers, the total number of pediatric sarcoma cases is far lower than adult cases because overall there […]

The Birth of Biosimilars in the US

We’ve become familiar, and even comfortable, with the concept of generic drugs. These medications are identical, or “bioequivalent,” to a brand-name pharmaceutical.   According to the U.S. Food and Drug Administration, generics must be chemically identical to and match the branded drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended […]